Podcasts about Lancet

India after Nigeria recorded highest number of zero-dose children in 2023. The lack of immunisation against deadly diseases puts children at risk of life-threatening diseases.  

‘Dancing Mania' - in which people spontaneously danced to exhaustion, some until they broke their ribs and subsequently died, took hold of Aachen, Germany on 24th June, 1374. We still don't really know why. Had the victims ingested ergot, a mould from rye bread that can inspire hallucinations? Was it a hysterical mass response to a stressful and traumatic environment? Or a kind of pre-smartphone flashmob?  In this episode, Arion, Rebecca and Olly consider the likely causes and cures for this curious episode, learn about the equally extraordinary phenomenon of Tarantism, and play ‘guess the Saintly disease'...  Further Reading: • ‘A Strange Case of Dancing Mania Struck Germany Six Centuries Ago', Smithsonian Magazine (2016) https://www.smithsonianmag.com/smart-news/strange-case-dancing-mania-struck-germany-six-centuries-ago-today-180959549/ • ‘A forgotten plague: making sense of dancing mania', The Lancet (2009): https://www.thelancet.com/article/S0140-6736(09)60386-X/fulltext • ‘Tarantism: A Rhythm For Your Soul'  (Giuliano Capani, 2008) on YouTube: https://www.youtube.com/watch?v=E6fB4oInT7A Love the show? Support us!  Join 

THE LANCET 2003;362:772-776Background: Angiotensin converting enzyme inhibitors (ACEi) reduce mortality and morbidity in patients with systolic heart failure (see CONSENSUS and SOLVD trials). However, registry data showed that up to 20% of patients with systolic heart failure were not taking ACEi. One of the frequent causes for intolerance to ACEi is cough. Angiotensin converting enzyme inhibitors work by blocking the conversion of angiotensin I to angiotensin II, a key step in the renin–angiotensin–aldosterone system (RAAS). Angiotensin II receptor blockers were tolerated in patients with systolic heart failure who were intolerant to ACEi. However, data on long term effectives as an alternative to ACEi were lacking.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Alternative trial sough to assess if the angiotensin-receptor blocker (ARB) candesartan, could improve outcomes in patients with systolic heart failure who are intolerant to ACEi.Patients: Eligible patients had left ventricular ejection fraction of 40% or less and NYHA class II, III or IV symptoms of at least 4 weeks duration. Patients had also to be intolerant to ACEi.Exclusion criteria were not provided in the main manuscript.Baseline characteristics: Patients were recruited from 618 centers in 26 countries. The trial randomized 2,028 patients – 1,013 randomized to receive candesartan and 1,015 to receive placebo.The average age of patients was 67 years and 68% were men. The average left ventricular ejection fraction was 30%. Cardiomyopathy was ischemic in 68% of the patients. The NYHA class was II in 48% of the patients, III in 49% and IV in 4%.Approximately 50% had hypertension, 27% had diabetes, 61% had prior myocardial infarction, 9% had stroke, 25% had atrial fibrillation and 14% were current smokers.At the time of enrollment, 85% were taking a diuretic, 46% were taking digoxin, 55% were taking beta-blockers and 24% were taking spironolactone.The most common reasons for ACEi intolerance were cough in 72% of the patients, hypotension in 13%, renal dysfunction in 12% and angioedema or anaphylaxis in 4%.Procedures: The trial was double-blinded. Patients were assigned in a 1:1 ratio to receive candesartan starting at 4 or 8mg once daily or placebo. The treatment was doubled every two weeks to a target dose of 32mg once daily.After randomization, follow up occurred at 2, 4, and 6 weeks, 6 months and every 4 months thereafter.Endpoints: The primary outcome was a composite of cardiovascular death or heart failure hospitalizations. All deaths were classified as cardiovascular unless there was a clear non-cardiac cause.Analysis was performed based on the intention-to-treat principle. The estimated sample size to have 80% power at 5% alpha was 2,000 patients. The sample size calculation assumed 18% relative risk reduction in the primary outcome with candesartan assuming a 15% annual event rate in the placebo arm.Results: The median follow up time was 34 months. The mean candesartan daily dose was 23mg at 6 months.Candesartan reduced the primary endpoint of cardiovascular death or heart failure hospitalizations (33.0% vs 40.0%, adjusted HR: 0.70, 95% CI: 0.60 – 0.81; p< 0.001). Candesartan reduced the individual components of the primary outcome - (21.6% vs 24.8%; p= 0.02) for cardiovascular death and (20.4% vs 28.2%; p< 0.001) for heart failure hospitalizations. All-cause death was also lower with candesartan (26.2% vs 29.2%, adjusted HR: 0.83, 95% CI: 0.70–0.99; p= 0.033). The number of patients who had any hospitalization as well as the total number of hospitalizations were numerically but not statistically significantly lower with candesartan (60.2% with candesartan vs 63.3%; p= 0.16) and (1,718 vs 1,835; p= 0.06).Candesartan was associated with more hypotension (3.7% vs 0.9%), more increase in creatinine (6.1% vs 2.7%) and more hyperkalemia (1.9% vs 0.3%). Angioedema occurred in three patients in the candesartan group and none in the placebo group. Cough occurred in two patients taking candesartan and four taking placebo.Authors reported no significant subgroup interactions, however, a corresponding graph was not provided.Conclusion: In patients with systolic heart failure who are intolerant to ACEi, candesartan reduced the primary composite outcome of cardiovascular death or heart failure hospitalizations with a number needed to treat of approximately of 14 patients over 34 months of follow up. Candesartan also reduced all-cause death with a number needed to treat of approximately 33 patients. Adverse events including hypotension, increase in creatinine and hyperkalemia were more common with candesartan.The reduction in the primary endpoint with candesartan was significant and offers an alternative for patients who are unable to tolerate ACEi. Of note, 72% of the patients enrolled in the trial were intolerant to ACEi due to cough. This trial did not include a head-to-head comparison between ARBs and ACEi, and therefore does not address which agent should be preferred as first-line therapy. Only 24% of participants were receiving spironolactone. The combination of ARBs with spironolactone, may increase the risk of adverse events, particularly hyperkalemia and kidney injury.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Join the Behind the Knife Surgical Oncology Team as we discuss the two key studies investigating optimal management strategies of neuroendocrine tumors of the small bowel. Hosts: - Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center - Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles. - Connor Chick, MD (@connor_chick) is a 2nd Year Surgical Oncology fellow at Ohio State University. - Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 1st Year Surgical Oncology fellow at MD Anderson. - Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a PGY-6 General Surgery resident at Brooke Army Medical Center Learning Objectives: In this episode we review two important papers that discuss optimal management strategies of neuroendocrine tumors (NET) of the small bowel.  The first paper by Singh and colleagues discusses the NETTER-2 trial investigating the role of radioligand therapy for NET as a first-line treatment.  The second article by Maxwell et all challenges surgical dogma regarding optimal debulking cutoffs for debulking of NET. Links to Papers Referenced in this Episode: 1.     Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203. https://pubmed.ncbi.nlm.nih.gov/38851203/ 2.     Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016 Jan;159(1):320-33. doi: 10.1016/j.surg.2015.05.040. Epub 2015 Oct 9. PMID: 26454679; PMCID: PMC4688152. https://pubmed.ncbi.nlm.nih.gov/26454679/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

In 2025, Creating Dementia Solutions is looking deeper into what The Lancet Commission on dementia prevention, intervention and care has indicated are ways people can reduce their risk of dementia.Lancet includes Diabetes treatment as one of those ways. In this episode, T R Shaw tells us how the Cereal City Sunrise Rotary Club has developed an action group in hopes of growing awareness about the disease and how its treated.Episode ResourcesThe Lancet Commission Risk Factors for DementiaMiles for Memories websiteMiles for Memories technologySherii Sherban talks to Community Matters about MFM technologyMore Creating Dementia Solutions episodes ABOUT MILES FOR MEMORIESMiles For Memories is a Calhoun County, Michigan organization created in 2013 to raise awareness and funds for Alzheimer's Disease. Later in 2014, the vision was expanded to include all types of dementia. MFM raises money each year through sponsorships, community events, and grants to gather funds to create local programming for both the person living with dementia and the caregiver. Along with local efforts, 20% of the funds to prevention-related dementia research. Miles for Memories is a committee of 70-plus volunteers and are always looking for more to get involved.

Saving the Sault – Where Truth Meets ActionSault Ste. Marie is at a tipping point.In this long-form episode, I explore the six critical challenges our city is facing—and how we can turn the tide. From economic fragility to the drug crisis, from government reliance to leadership voids, I offer bold but achievable ideas to help the Sault thrive again.This isn't political. It's personal. And it starts with honesty, unity, and hope.

Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode.  Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here.  Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months.  The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured?  Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients.  And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. John Sweetenham Dr. Marc Braunstein   @docbraunstein     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS

Can you be both a scientist and a mystic? In this extraordinary episode, Professor Selena Bartlett speaks with Dr. Anona Blackwell — a Lancet-published academic, former consultant physician, and author of From Medic to Mystic — about the turning point where evidence-based medicine no longer had all the answers.Raised in rural poverty in Wales and rising to the heights of British medical academia, Dr. Blackwell quietly navigated a parallel world of intuitive experiences, energy healing, and psychic insight. For decades, she kept this side hidden. Now, at 75, she's sharing it all — and helping rewire our understanding of medicine and healing.In this conversation, we explore:·       The moments science couldn't explain — and why she couldn't ignore them·       How trauma, intuition, and healing intersect in clinical settings·       The courage it takes to speak about the unseen in a sceptical world·       Why the future of medicine must integrate both body and energy, logic and intuitionDr. Blackwell's story challenges the idea that you must choose between science and spirit. Instead, she shows us that healing lives at the intersection of both.Her memoir, From Medic to Mystic, is available now.https://www.amazon.com/Medic-Mystic-Academic-Physicians-Paranormal/dp/1068511001Listen and discover what it really means to rewire medicine. Support the showSubscribe and support the podcast at https://www.buzzsprout.com/367319/supporters/newLearn more at www.profselenabartlett.com

Episode 69: The Hidden Harms of Vaping and Nicotine Pouches - What Dental Professionals Need to Know Hosts: Tabitha Acret (Australia) & Melissa Obrotka (USA)  Episode Description  In this critical episode, Tabitha and Melissa tackle one of the most pressing and misunderstood topics in oral health today: the harms of vaping and nicotine pouches like Zyn. Far from being "harmless alternatives," these products present significant risks that dental professionals need to understand and address. Key Topics Covered What Are Vapes and Nicotine Pouches?

Le "paradoxe français" désigne une observation intrigante : les Français, malgré une alimentation riche en graisses saturées (fromages, beurre, charcuterie), ont un taux relativement bas de maladies cardiovasculaires, en comparaison avec d'autres pays occidentaux comme les États-Unis. Cette contradiction apparente a été mise sous les projecteurs aux États-Unis le 17 novembre 1991, lors d'un épisode de l'émission très populaire 60 Minutes diffusée sur CBS. Le segment, intitulé "The French Paradox", présentait l'idée que la consommation régulière de vin rouge par les Français pourrait être la clé de leur bonne santé cardiovasculaire.L'impact de cette émission a été immédiat : selon les données du Wine Market Council, les ventes de vin rouge ont augmenté de 44 % aux États-Unis dans les mois qui ont suivi. En 1992, le vin rouge représentait environ 70 % des nouvelles ventes de vin sur le marché américain, contre seulement 50 % l'année précédente. Certaines marques françaises comme Château Lafite Rothschild ont vu leur popularité exploser, et les importations de vin français ont fortement progressé.Sur le plan scientifique, l'un des principaux promoteurs de ce concept était le chercheur Serge Renaud de l'INSERM à Lyon. Dans un article publié en 1992 dans The Lancet, il avance que la consommation modérée de vin rouge – un à deux verres par jour – pourrait réduire le risque de maladies coronariennes de 40 %. Le vin rouge contient en effet des polyphénols, dont le plus connu est le resvératrol, un antioxydant présent dans la peau du raisin. Des études comme celle de J.P. Fremont (1999, Life Sciences) ont suggéré que le resvératrol inhibe l'agrégation des plaquettes et protège les vaisseaux sanguins.Le "paradoxe français" est alors devenu un argument marketing massif. L'industrie vinicole, en France comme aux États-Unis, s'en est emparée pour promouvoir le vin rouge comme un produit "santé". Cette stratégie a contribué à modifier l'image du vin outre-Atlantique, le faisant passer d'un produit de luxe européen à un choix de consommation perçu comme bénéfique.Cependant, cette idée a été nuancée fortement depuis. Aujourd'hui on sait que scientifiquement, la consommation modérée d'alcool n'est pas totalement sans risque, même à faibles doses.Citons l'étude de référence : The Lancet, 2018 – Global Burden of Disease StudyIl s'agit de l'une des études les plus vastes jamais réalisées sur le sujet, couvrant plus de 28 millions de personnes dans 195 pays. Elle conclut que le niveau de consommation d'alcool le plus sûr est zéro. Même à faibles doses, l'alcool augmente les risques de certains cancers, de maladies cardiovasculaires et de blessures.Cette étude remet donc totalement en cause l'idée selon laquelle une consommation modérée, comme un verre de vin par jour, pourrait être bénéfique pour la santé. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Was geschieht mit unserem Bewusstsein nach dem Tod? Pim van Lommel blickt dem Tod täglich ins Gesicht – als Kardiologe rettet er Leben, als Forscher erkundet er, was danach geschieht. Seine Patienten kehren zurück mit Geschichten, die ihr Weltbild verändern: Sie schweben über ihren leblosen Körpern, wandeln durch Tunnel aus purem Licht, begegnen längst verstorbenen Seelen. Erfahre in diesem Podcast, wie Menschen nach Nahtoderfahrungen ihre Lebenseinstellung radikal verändern – und warum sie plötzlich keine Angst mehr vor dem Sterben haben. Pim van Lommel spricht über Studien, die nahelegen: Unser Bewusstsein überlebt den klinischen Tod. Ein Mann, dessen Forschung in Fachzeitschriften wie "The Lancet" für Aufsehen sorgte. Pim van Lommels Buch: "Endloses Bewusstsein: Neue medizinische Fakten zur Nahtoderfahrung" https://amzn.to/4eVmoVc   Die geäußerten Meinungen und Aussagen dienen ausschließlich Bildungs- und Informationszwecken, ersetzen jedoch keine therapeutische oder medizinische Beratung. Bereit Dein Genie zu entdecken? Lebe selbstbewusster, freier & erfolgreicher mit genialen Video-Kursen aus unserer Online-Akademie: https://akademie.maximmankevich.com/  

For decades, the great fear was overpopulation. Now it's the opposite. How did this happen — and what's being done about it? (Part one of a three-part series, “Cradle to Grave.”) SOURCES:Matthias Doepke, professor of economics at the London School of Economics.Amy Froide, professor of history at the University of Maryland, Baltimore County.Diana Laird, professor of obstetrics and gynecology at the University of California, San Francisco.Catherine Pakaluk, professor of economics at The Catholic University of America. RESOURCES:"Fertility Rate, Total for the United States," (Federal Reserve Bank of St. Louis, 2025)."Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021," (The Lancet, 2024)."Suddenly There Aren't Enough Babies. The Whole World Is Alarmed." by Greg Ip and Janet Adamy (The Wall Street Journal, 2024)."Taxing bachelors and proposing marriage lotteries – how superpowers addressed declining birthrates in the past," by Amy Froide (University of Maryland, 2021)."Is Fertility a Leading Economic Indicator?" by Kasey Buckles, Daniel Hungerman, and Steven Lugauer (National Bureau of Economic Research, 2018).The King's Midwife: A History and Mystery of Madame du Coudray, by Nina Rattner Gelbart (1999).The Population Bomb, by Paul Ehrlich (1970)."An Economic Analysis of Fertility," by Gary Becker (National Bureau of Economic Research, 1960). EXTRAS:"What Will Be the Consequences of the Latest Prenatal-Testing Technologies?" by Freakonomics Radio (2011).

In this episode of, Dr. Sergio Zanotti explores the vital role of enteral nutrition in the ICU—a foundational element in the prevention and treatment of disease-related malnutrition among critically ill patients. He is joined by Dr. Leah Gramlich, a distinguished gastroenterologist and physician nutrition specialist from the Royal Alexandra Hospital in Alberta, Canada. Dr. Gramlich is a Professor of Medicine at the University of Alberta and the founding president of the Canadian Nutrition Society. She has also served on the Board of Directors for the American Society for Parenteral and Enteral Nutrition and chaired the Canadian Malnutrition Task Force, bringing deep expertise to this essential topic. Additional resources: Enteral Nutrition in Hospitalized Adults. Lead Gramlich, Peggi Guenter. New Engl J Med 2025: https://pubmed.ncbi.nlm.nih.gov/40239069/ Individualized nutritional support in medical inpatients at nutritional risk: a randomized clinical trial. The EFFORT Clinical Trial. Lancet 2019: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32776-4/abstract Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3). Lancet Respir Med 2023: https://pubmed.ncbi.nlm.nih.gov/36958363/ The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein): an international, multicentre, pragmatic, registry-based randomised trial. Lancet 2023: https://pubmed.ncbi.nlm.nih.gov/36708732/ Books mentioned in this episode: The Overstory: A Novel. By Richard Powers: https://bit.ly/43Drra1

The Food Professor Podcast closes out its fifth season (sort of) with a sizzling, two-guest double feature and a feast of food industry insights.Co-hosts Michael LeBlanc and Dr. Sylvain Charlebois kick things off with a robust news round-up, starting with the Competition Bureau's lawsuit against DoorDash. The case alleges deceptive pricing practices that could set a major precedent in Canada's rapidly evolving food delivery sector. Next up is a conversation about GLP-1 drugs like Ozempic, and their surprising ripple effects across the food and restaurant industries. With major players like McDonald's flagging GLP-1's impact on consumer demand, the hosts unpack how appetite suppression could force chains to rethink menus and marketing.Turning to politics, the duo dives into the return of Bill C-202, which aims to legislate permanent protection for supply-managed sectors like dairy. Sylvain, fresh from testifying before Senate, challenges the notion that legislation ensures economic security, arguing that this approach stifles innovation and shrinks global opportunities for Canada's dairy sector. The conversation highlights deeper questions about food affordability, trade readiness, and long-term resilience in Canadian agriculture.The episode then shifts to the guest segment, welcoming Daniel Vaughn, Texas Monthly's Barbecue Editor and the man behind the publication's iconic “Top 50 Barbecue Joints in Texas” list. Daniel shares his personal journey from Ohio to Texas BBQ fanatic, reveals the meticulous tasting process behind the prestigious list, and highlights innovations shaping the future of craft barbecue—from smoked lamb to Vietnamese fusion. He also reflects on the human side of the industry, including stories of pitmasters overcoming illness, personal loss, and economic challenges, all while pursuing culinary greatness.Wrapping the episode, Ransom Hawley, CEO of Caddle and presenting sponsor of the podcast, joins to share exclusive insights from a new back-to-school consumer study. He reveals that two-thirds of Canadian parents begin planning in late spring, and that private-label grocery products are increasingly popular—especially among families with younger children. He discusses emotional purchase behavior, the importance of online research, and how grocers and retailers can tailor promotions for maximum impact.With bold opinions, brisket, and back-to-school tips, this finale serves up equal parts smoke and strategy. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

THE LANCET 2003;362:767-771Background: Angiotensin II which plays a role in ventricular remodeling and progression of heart failure can be produced by pathways independent of angiotensin convening enzyme. Preliminary studies showed that the combination of angiotensin II blockers with angiotensin-converting enzyme inhibitors (ACEi) improves hemodynamics and reduces ventricular remodeling.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial sough to assess if adding the angiotensin-receptor blocker (ARB), candesartan, to ACEi could improve outcomes in patients with systolic heart failure.Patients: Eligible patients had left ventricular ejection fraction of 40% or less within the previous 6 months, and NYHA class II, III or IV symptoms. Patients with NYHA class II symptoms had to have cardiac-related hospitalization within 6 months. Patients also had to have treatment with ACEi at a constant dose for at least 30 days.Exclusion criteria were not provided in the main manuscript.Baseline characteristics: Patients were recruited from 618 centers in 26 countries. The trial randomized 2,548 patients – 1,276 randomized to receive candesartan and 1,272 to receive placebo.The average age of patients was 64 years and 79% were men. The average left ventricular ejection fraction was 28%. Cardiomyopathy was ischemic in 62% of the patients. The NYHA class was II in 24% of the patients, III in 73% and IV in 3%.Approximately 48% had hypertension, 30% had diabetes, 56% had prior myocardial infarction, 9% had stroke, 27% had atrial fibrillation and 17% were current smokers.At the time of enrollment, 90% were taking a diuretic, 58% were taking digoxin, 55% were taking beta-blockers, 17% were taking spironolactone and all but two patients were taking ACEi.Procedures: The trial was double-blinded. Patients were assigned in a 1:1 ratio to receive candesartan starting at 4 or 8mg once daily or placebo. The treatment was doubled every two weeks to a target dose of 32mg once daily.After randomization, follow up occurred at 2, 4, and 6 weeks, 6 months and every 4 months thereafter.Endpoints: The primary outcome was a composite of cardiovascular death or heart failure hospitalizations. All deaths were classified as cardiovascular unless there was a clear non-cardiac cause.Analysis was performed based on the intention-to-treat principle. The estimated sample size to have 80% power at 5% alpha was 2,300 patients. The sample size calculation assumed 16% relative risk reduction in the primary outcome with candesartan assuming an 18% annual event rate in the placebo arm.Results: The median follow up time was 41 months. The mean candesartan daily dose was 24mg at 6 months.Candesartan reduced the primary endpoint of cardiovascular death or heart failure hospitalizations (37.9% vs 42.3%, adjusted HR: 0.85, 95% CI: 0.75 – 0.96; p= 0.01). Candesartan reduced the individual components of the primary outcome - (23.7% vs 27.3%; p= 0.021) for cardiovascular death and (24.2% vs 28.0%; p= 0.018) for heart failure hospitalizations. There was no significant reduction in all-cause death (29.5% with candesartan vs 32.4%; p= 0.105). The number of patients who had any hospitalization was similar in both groups (66.8% with candesartan vs 67.5%; p= 0.7), however, the total number of hospitalizations was lower with candesartan (2,462 vs 2,798; p= 0.023).Serum creatinine at least doubled in 7% of the patients in the candesartan group vs 6% in the placebo group. In the subset of patients taking spironolactone, serum creatinine at least double in 11% of the patients taking candesartan compared to 4% of the patients taking placebo.Hyperkalemia, defined as serum potassium of 6 mmol/L or higher, occurred in 3% of the patients in the candesartan group vs 1% in the placebo group. In the subset of patients taking spironolactone, hyperkalemia occurred in 4% of the patients taking candesartan compared to 1% of the patients taking placebo.There were two cases of angioedema in the candesartan group and three in the placebo group. All patients were taking an ACEi.There were no significant subgroup interactions, including in patients taking both beta-blockers and ACEi at baseline.Conclusion: In patients with systolic heart failure, adding candesartan to an ACEi reduced the primary composite outcome of cardiovascular death or heart failure hospitalizations with a number needed to treat of approximately of 23 patients over 41 months of follow up. The total number of all-cause hospitalizations was reduced by 336 with candesartan. All-cause death was not significantly reduced with candesartan.While the results of the trial appear impressive, the high number of adverse outcomes with candesartan in patients taking spironolactone is concerning. Spironolactone led to significant reduction in all-cause mortality in patients with systolic heart failure, as seen in the RALES trial, and should be prioritized over adding candesartan. Notably, fewer than 20% of patients in the trial were on spironolactone at baseline; if more had been, the incremental benefit of candesartan would likely have been reduced due to an increased risk of adverse effects from triple neurohormonal blockade (ACEi, ARBs, and mineralocorticoid receptor antagonists). Furthermore, spironolactone acts by blocking the aldosterone receptor, which is downstream in the renin–angiotensin–aldosterone system. Since candesartan blocks angiotensin II upstream in the same pathway, simultaneous inhibition at multiple points may lead to diminishing benefit.Finally, the differences observed in the subgroup of patients on beta-blockers between this trial and Val-HeFT remain unclear and may simply reflect the play of chance. As we previously discussed, patients receiving both an ACEi and beta-blockers had worse outcomes with valsartan in the Val-HeFT trial.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167Articles discussed in this podcast episode include:Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloClaudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloRelacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo#asco2025Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

An unhealthy diet is the leading risk factor for death in the US, according to research published in the Lancet. Studies show a healthy diet can reverse chronic diseases.

This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode of The Food Professor Podcast, recorded live at the SIAL Food Innovation Show in Toronto, opens with co-hosts Michael LeBlanc and Dr. Sylvain Charlebois breaking down the week's top food and retail stories.First, they tackle the evolving Canadian political stance on supply management. Prime Minister Carney's reversal in support of Bill C-282 suggests renewed government protectionism in agricultural trade, potentially complicating future international deals. Sylvain, who testified against the bill, argues for a smarter, more competitive dairy sector rather than entrenching status quo inefficiencies.Next, they examine the return of Trump-era tariffs, including a 50% levy on aluminum. This move could squeeze margins in the canned food and craft beer sectors. Sylvain praises the Canadian government's decision not to retaliate immediately, calling it a strategic pause rather than knee-jerk nationalism. Then they discuss NielsenIQ data revealing that Canadians are cutting back on U.S. goods—not necessarily out of patriotism, but due to anti-American sentiment—while failing to significantly boost local Canadian brands.The final news item highlights the surprising global shortage of black pepper, linked to poor climate and farming shifts. As Sylvain jokes, barbecue fans like Michael may want to stock up on their secret weapon: 16-mesh pepper!The spotlight then shifts to special guest Vince Sgabellone, Food Service Industry Analyst at Circana Canada. Vince shares compelling insights from the frontlines of Canadian food service. A major trend? The explosion of global cuisine. Whether it's falafel shops, Nepalese momo dumplings, or Ethiopian cafés, Canadians are craving authentic international flavors—even from mainstream chains like Recipe Unlimited.Vince attributes much of this shift to immigration and younger generations of diners. One-third of all restaurant visits now come from people of color, and that number is even higher among Gen Z. These consumers are reshaping the restaurant landscape, fueling growth in fast casual dining and independent eateries with strong ethnic roots.He also reveals that dining out remains resilient in Canada, especially compared to a softening U.S. market. Delivery and takeout are climbing again, even as lunch remains the industry's weakest segment due to remote work. The growing popularity of solo dining, driven by changing social patterns and younger demographics, is creating new design opportunities for restaurant operators.This episode is rich in data, spiced with insights, and ends with a wild story about an elephant raiding a grocery store in Thailand—a perfect reminder that food always finds a way to surprise us. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Editors of CMI Comms, Josh Davis, Erin McCreary and Emily McDonald return for round 2 taking turns to summarise and discuss late-breaker trials presented at ESCMID Global 2025 in Vienna, and whether or not these trials should change your practice. Part 2 covers the ALABAMA trial exploring the safety of penicillin-allergy delabelling using the penicillin allergy assessment pathway, the SOLARIO trial investigating short (≤7 days!) versus long (≥4 weeks) antibiotic courses for orthopaedic infections, the EAGLE-1 trial assessing oral gepotidacin for gonorrhoea, a randomised clinical trial (RCT) from Thailand on oral fosfomycin as carbapenem-sparing, de-escalating therapy in complicated UTIs, and a double-blind RCT from Israel comparing neutralising plasma to placebo for West Nile fever.    This episode was peer reviewed by Dr. Emanuele Rando of Hospital Universitario Virgen Macarena, Seville, Spain and is the second of this two-part series covering selected clinical trials presented at ESCMID Global 2025.  Late-breaker trialsSandoe J, et al. Penicillin allergy assessment pathway versus usual clinical care for primary care patients with a penicillin allergy record to assess safety, de-labelling and antibiotic prescribing: The ALABAMA randomised controlled trialAngkanavisan K, et al. Oral fosfomycin after carbapenems as de-escalating therapy in complicated urinary tract infection: A randomisedcontrolled trialCanetti M, et al. Neutralising plasma versus placebo for hospitalised patients with West Nile fever: a double-blind randomised controlled trialDudareva M, et al. Short or long antibiotic regimes in orthopaedics: the SOLARIO multicentre randomised controlled trialWilson, J. Phase 3 randomised trial of oral gepotidacin for the treatment of uncomplicated gonorrhoea (EAGLE-1) ReferencesIDSA. Public Comment: IDSA Guideline on Management and Treatment of Complicated Urinary Tract Infections; 19 Feb - 19 March 2025.Mostashari F, et al. Epidemic West Nile encephalitis, New York, 1999. Lancet. 2001. doi: 10.1016/S0140-6736(01)05480-0Angus DC. Optimizing the Trade-off Between Learning and Doing in a Pandemic. JAMA. 2020. doi: 10.1001/jama.2020.4984Dudareva M. In: The 42nd Annual Meeting of the European Bone & Joint Infection Society. Barcelona, Spain: 26-28 Sept 2024. Li HK, et al. Oral versus Intravenous Antibiotics for Bone and Joint Infection (OVIVA). NEJM. 2019 doi: 10.1056/NEJMoa1710926

Welcome back to Call the Midwife, a special mini-series from Growing - this mini series is your go-to shortcut to everything you should know about pregnancy. Whether you're newly pregnant, in your third trimester, or just planning ahead, this series is here to guide you with warmth, evidence, and real-life insight.In this episode, we're talking about something simple but so important: safe sleep during pregnancy. You've probably heard that sleeping on your side from 28 weeks is recommended - but do you know why?We unpack the latest Australian guidelines and evidence, including a key study published in The Lancet, linking side-sleeping from 28 weeks with a significantly reduced risk of stillbirth. Plus, we share practical tips for making side-sleeping easier and more comfortable - hello, Sleepybelly pillow!✨ This is essential listening for every pregnant woman who wants real, actionable advice backed by science.Why side sleeping from 28 weeks mattersHow to get more comfortable (tip: your pillow matters!)Tools and tricks for a better night's sleep in late pregnancyHow these small changes can make a big impactSleepybelly Pregnancy Pillow – Support your bump, back and hips with Sleepybelly. Enjoy a 30-night risk-free trial and get 10% off with code GROWING10The Lancet Study on Stillbirth & Sleep PositionRed Nose Australia – Trusted, evidence-based advice on sleep safety for pregnancy and beyondHuge thanks to our friends at Sleepybelly – the ultimate pregnancy pillow for bump and back support, proudly designed in Australia and loved by thousands of mums.What You'll Learn:Resources & Links:Share this ep with a fellow mum-to-be or post it to your Instagram stories and tag us at @growingthepodcast. It could be just the info she needs.

00:02:34;18 - 00:05:33;00Colorado's Gender Identity Policy for Youth CampsColorado mandates youth camps, including Christian Camp Idra Hagee, to allow facility use based on self-declared gender identity, sparking controversy. The camp's failed lawsuit for a religious exemption underscores tensions between state policy and religious freedom, with critics arguing it prioritizes feelings over safety. 00:20:38;15 - 00:24:54;16UN Treaty on AI-Generated Child PornographyA proposed UN treaty may permit AI-generated child sexual abuse imagery as “harm reduction” for pedophiles. Critics condemn it as morally reprehensible, arguing it fuels demand and strains law enforcement, contrasting with U.S. laws in 38 states targeting such material. 01:15:45;25 - 01:22:44;06Trump Administration and Digital Control Grid ConcernsFears grow that the Trump administration is building a digital control grid using AI, digital IDs, and stablecoins, centralizing financial control and enabling mass surveillance. Missing $21 trillion in government funds and crypto-friendly policies heighten concerns of a technocratic super-surveillance state. 01:26:13;18 - 01:28:13;08German Pensioner's Speech Crime ConvictionA 73-year-old German pensioner faces 75 days in prison for repeating the banned phrase “Alles für Deutschland,” linked to National Socialist slogans. His inability to pay a €4,500 fine highlights Germany's strict speech crime laws and their chilling effect on free expression. 01:35:03;06 - 01:38:43;14Georgia Mother Arrested for Leaving Kids Home AloneAlexandra Woodward faces five years in prison for briefly leaving her 8- and 10-year-old sons alone in Georgia. Despite their safety, the father's 911 call led to her arrest, exposing state overreach and inconsistent laws on child autonomy versus gender decisions. 02:09:55;23 - 02:14:27;16Escalation Toward World War IIIGerald Celente warns of World War III risks, citing Germany's $1 trillion defense budget, troop deployments near Russia, and missile supplies to Ukraine. He criticizes the military-industrial complex for enriching elites while economies stagnate, ignoring consumer-driven growth. 02:17:45;28 - 02:19:57;07Gaza Conflict and Lack of OutrageOver 100,000 deaths in Gaza, including 50,000 children, per Lancet, draw little celebrity or media outrage, unlike Vietnam War protests. Celente condemns U.S. backing of Israel's actions, including West Bank settlements, as war crimes ignored by the West. 02:33:25;28 - 02:38:42;19Commercial Real Estate and AI Bubble CollapseCelente predicts a commercial real estate crash due to 54% office occupancy and expiring leases, risking bank failures like 2023's Silicon Valley Bank. He also foresees an AI bubble burst, akin to the 2000 dot-com crash, potentially collapsing equity markets and boosting gold prices. 02:54:31;20 - 02:58:16;21Israel's Samson Option and Middle East TensionsCelente highlights Israel's “Samson Option,” a nuclear strategy to destroy enemies if threatened, escalating Middle East tensions. He labels Israel an apartheid state, per Human Rights Watch, and criticizes U.S. support for its Gaza actions and potential Iran conflict, risking global catastrophe. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

00:02:34;18 - 00:05:33;00Colorado's Gender Identity Policy for Youth CampsColorado mandates youth camps, including Christian Camp Idra Hagee, to allow facility use based on self-declared gender identity, sparking controversy. The camp's failed lawsuit for a religious exemption underscores tensions between state policy and religious freedom, with critics arguing it prioritizes feelings over safety. 00:20:38;15 - 00:24:54;16UN Treaty on AI-Generated Child PornographyA proposed UN treaty may permit AI-generated child sexual abuse imagery as “harm reduction” for pedophiles. Critics condemn it as morally reprehensible, arguing it fuels demand and strains law enforcement, contrasting with U.S. laws in 38 states targeting such material. 01:15:45;25 - 01:22:44;06Trump Administration and Digital Control Grid ConcernsFears grow that the Trump administration is building a digital control grid using AI, digital IDs, and stablecoins, centralizing financial control and enabling mass surveillance. Missing $21 trillion in government funds and crypto-friendly policies heighten concerns of a technocratic super-surveillance state. 01:26:13;18 - 01:28:13;08German Pensioner's Speech Crime ConvictionA 73-year-old German pensioner faces 75 days in prison for repeating the banned phrase “Alles für Deutschland,” linked to National Socialist slogans. His inability to pay a €4,500 fine highlights Germany's strict speech crime laws and their chilling effect on free expression. 01:35:03;06 - 01:38:43;14Georgia Mother Arrested for Leaving Kids Home AloneAlexandra Woodward faces five years in prison for briefly leaving her 8- and 10-year-old sons alone in Georgia. Despite their safety, the father's 911 call led to her arrest, exposing state overreach and inconsistent laws on child autonomy versus gender decisions. 02:09:55;23 - 02:14:27;16Escalation Toward World War IIIGerald Celente warns of World War III risks, citing Germany's $1 trillion defense budget, troop deployments near Russia, and missile supplies to Ukraine. He criticizes the military-industrial complex for enriching elites while economies stagnate, ignoring consumer-driven growth. 02:17:45;28 - 02:19:57;07Gaza Conflict and Lack of OutrageOver 100,000 deaths in Gaza, including 50,000 children, per Lancet, draw little celebrity or media outrage, unlike Vietnam War protests. Celente condemns U.S. backing of Israel's actions, including West Bank settlements, as war crimes ignored by the West. 02:33:25;28 - 02:38:42;19Commercial Real Estate and AI Bubble CollapseCelente predicts a commercial real estate crash due to 54% office occupancy and expiring leases, risking bank failures like 2023's Silicon Valley Bank. He also foresees an AI bubble burst, akin to the 2000 dot-com crash, potentially collapsing equity markets and boosting gold prices. 02:54:31;20 - 02:58:16;21Israel's Samson Option and Middle East TensionsCelente highlights Israel's “Samson Option,” a nuclear strategy to destroy enemies if threatened, escalating Middle East tensions. He labels Israel an apartheid state, per Human Rights Watch, and criticizes U.S. support for its Gaza actions and potential Iran conflict, risking global catastrophe. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Behind the skyscrapers and luxurious resorts of the United Arab Emirates, a silent health crisis is looming. According to a study published in The Lancet, the prevalence of overweight and obesity among adult men in the UAE is set to rise from 84 percent in 2021 to 94 percent by 2050, placing the country among the worst affected in the world. This epidemic is fuelled by unbalanced eating habits, a growing reliance on home deliveries and a sedentary lifestyle. The consequences are serious: diabetes, hypertension and cardiovascular disease. The Emirati authorities are taking action, in particular by targeting younger generations, but significant progress still needs to be made. Our team on the ground reports.

This episode of The Food Professor Podcast is steeped in insights, storytelling, and smoky Texas flavour. Hosts Michael LeBlanc and Dr. Sylvain Charlebois kick off with a deep dive into the state of Canadian agri-food policy, tariffs, and food inflation before welcoming a very special guest: Tonia Jahshan, Founder and CEO of Sipology.Broadcasting remotely from Texas, Sylvain shares updates from his new role as head of the prestigious Masters in Agribusiness program at Texas A&M University—ranked #1 in the U.S. and #3 globally. He offers behind-the-scenes insights into the world of American ag education, donor-funded infrastructure, and his leadership plans. Amidst meetings with deans and exploring campus, Sylvain visits a Texas institution of another kind—Buc-ee's, the legendary convenience store-meets-theme-park known for its brisket, wall of jerky, and award-winning bathrooms. The hosts revel in Buc-ee's cult status and then Michael highlights the newly released Texas Monthly Top 50 BBQ list, the Michelin Guide of Texas barbecue. Sylvain, a BBQ enthusiast, is already planning future brisket pilgrimages.  Congrats to our guest on the #pod from earlier this year Chuck Charnichart from Barb's BQ for making the list!!From Texas to Toronto, the episode pivots to policy with an analysis of Prime Minister Mark Carney's new mandate letter. Sylvain critiques its lack of clarity for the agri-food sector, calling for a shift from farm-gate thinking to value-chain strategy. The hosts then turn to the thorny issue of tea tariffs, which are hitting Canadian importers hard despite recent government reprieves. With tea being a $1.3 billion market in Canada—and nearly all of it imported—these tariffs are creating real cost pressures. The duo also revisits the long-running bread price-fixing investigation, discussing Loblaw's recent $500 million class action settlement and why the Competition Bureau's probe remains unresolved.In the second half of the episode, Tonia Jahshan joins the pod live from the SIAL Canada show floor. The inspirational founder of Sipology (formerly Steeped Tea) shares her origin story: how a single sip of loose-leaf Earl Grey in Nova Scotia after a miscarriage led to a wellness-focused tea empire. From launching a side hustle to pitching on Dragons' Den, growing to 8,000 consultants, and creating Health Canada-approved products like menopause relief teas and fizzy matchas, Tonia's entrepreneurial journey is one of resilience, reinvention, and remarkable growth. Now expanding globally and embracing an omni-channel model, she's brewing up a bold new future for Sipology.With a rich mix of policy insights, business strategy, entrepreneurial inspiration—and a side of Texas BBQ—this episode is a flavourful must-listen. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

In the summer of 1518, a woman stepped into the streets of Strasbourg and began to dance. She didn't stop for hours. Then days. Then weeks. Soon, hundreds had joined her—and some never stopped.In this episode of our history-sode series, we dive into the mysterious and very real Dancing Plague of 1518. Why did it happen? Could people really dance themselves to death? And how did an entire city respond to the chaos? You'll find out in this strange but true tale from the past.Waller, John. A Time to Dance, A Time to Die: The Extraordinary Story of the Dancing Plague of 1518. Icon Books, 2008.The Lancet, “Dancing Plague of 1518” (2004): https://www.thelancet.comHistory.com Editors. “The Dancing Plague of 1518.” History Channel, https://www.history.com/news/what-was-the-dancing-plague-of-1518Smithsonian Magazine. “The Dancing Plague of 1518.” https://www.smithsonianmag.com

A new analysis by the Ludwig Institute for Shared Economic Policy finds 1 in 4 middle class households living in functional unemployment, not earning enough or making the benefits that enable them to live a comfortable life. The BIDEN ADMIN was cooking the books. HHS secretary Bobby Kennedy says the NIH will no longer publish in big pharma-controlled scientific journals like The Lancet. A lifelong democrat realizes he'd been brainwashed before becoming a republican.

Dr Alex Ezeh, Global Health expert and contributor to the Lancet Commission on Adolescent Health and Wellbeing, joins John Maytham to unpack urgent warnings from the latest report. With over one billion adolescents projected to face serious health risks by 2030, Dr. Ezeh outlines the global crises affecting young people — rising obesity, worsening mental health, climate stress, and a digitally saturated world. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Welcome to the Plant-Based Canada Podcast! In today's episode, we're joined by Dr. Amar Lalia to discuss the upcoming EAT-Lancet Commission 2.0 report on the planetary health diet. We'll explore key topics including food systems, justice, and environmental impacts, all set to be unveiled in Fall 2025.Dr. Laila is a postdoctoral fellow at the Stockholm Resilience Centre, Sweden, and the University of Guelph, Canada. Amar completed his PhD at the University of Guelph, where he explored the connection between food literacy and food waste among Canadian families with young children, utilizing both qualitative and quantitative methods. Amar is passionate about food systems justice and his goal is to contribute to just and sustainable food system transformation through improvements in food environments so that they are healthy and sustainable for everyone.Resources:EAT-Lancet CommissionA comment paper in the Lancet referring to the EL2 commission's focus on justiceHigh Level Panel of Experts on Food Security and Nutrition reportsFAO's State of food security and nutritionFood System Economics Commission (to provide exact numbers referred to in the episode discussion):The Food System Economics Commission estimates the hidden costs of global food systems at approximately $15 trillion USD per year. However, the net benefits of transforming the food system are valued between $5 to $10 trillion USD annually, which is equivalent to 4-8% of global GDP (2020).In contrast, the cost of transforming the global food system is only 0.2-0.4% of global GDP, making it clearly affordable compared to the substantial global benefits—roughly $20-40 trillion USD.For full details, check out the Executive Summary.Dr. Amar Laila's Socials:ResearchGateORCIDLinkedInPlant-Based Canada's Socials:Instagram  (@plantbasedcanadaorg)FacebookWebsite  (https://www.plantbasedcanada.org/)X / Twitter @PBC_orgBonus PromotionCheck out University of Guelph's online Plant-Based Nutrition Certificate. Each 4-week course will guide you through essential plant-based topics including nutritional benefits, disease prevention, and environmental impacts. You can also customize your learning with unique courses such as Plant-Based Diets for Athletes and Implementing a Plant-Based Diet at Home. As the first university-level plant-based certificate in Canada, you'll explore current research, learn from leading industry experts, and join a community of like-minded people. Use our exclusive discount code PBC2025 to save 10% on all Plant-Based Nutrition Certificate courses. uoguel.ph/pbn.Thank you for tuning in! Make sure to subscribe to the Plant-Based Canada Podcast so you get notified when new episodes are published. This episode was hosted by Stephanie Nishi RD, PhD.Support the show

Show notes:Did you know that ultra processed foods (UPFs) make 57% of the average British diet and up to 80% when it comes to children and people with lower incomes. And that the major food and drink companies lobbied to block the UK government's efforts pushing for discounts on healthier and minimally processed products In the Indian sub-continent meanwhile, an average household derives more calories from processed foods than fruits (The Lancet study 2020). What is staggering is that this diet has been reshaped over the course of a single generation. While regulations around ultra-processed foods are tightening in both the UK and India, food regulations in India are considered weak, ambiguous, and industry-friendly, leading to a lack of strong front-of-pack labelling and effective advertising restrictions. Last year I reached out to the Access to Nutrition Initiative (ATNI) in India - a pivotal global foundation dedicated to transforming the food industry to learn more about their work and the ATNI's India Index. The India Index 2023 assesses the performance of the 20 largest food and beverage manufacturers of India. The findings based on 1,901 products are not unexpected but still staggering

Reference:  St Peter, et al. Appendicectomy versus antibiotics for acute uncomplicated appendicitis in children: an open-label, international, multicentre, randomized noni-inferiority trial. The Lancet. Jan 2025 Date: March 19, 2025 Guest Skeptic: Dr. Camille Wu is a paediatric surgeon based at Sydney Children's Hospital where she is the Head of Department. She is also on the […] The post SGEM#476: Cuts like a Knife or Antibiotics for Pediatric Appendicitis first appeared on The Skeptics Guide to Emergency Medicine.

A Lancet study warns of consequences for HIV prevention if PEPFAR loses funding, potentially millions of new pediatric HIV cases and increased AIDS-related deaths. Medicare Part D is highlighted, with research linking subsidy loss to higher mortality rates. A report from BMJ notes a 3.1% decline in U.S. drug overdose deaths, signaling a possible peak in the fentanyl crisis.

Lancet 1999;353:2001-07Background: Beta-blockers directly reduce cardiac contractility and myocardial oxygen demand. For decades, they were avoided in patients with acute and chronic heart failure over concerns they would facilitate decompensation of the condition. The therapeutic cornerstones of treatment, prior to the modern era of clinical trials, focused on managing symptoms and quality of life with diuretics and inotropic agents like digoxin; however, new paradigms were arising that focused on addressing neurohormonal mechanisms of chronic disease that were over-activated in the failing heart. The first major success came with inhibition of the renin angiotensin aldosterone system with angiotensin converting enzyme inhibitors whose effect on mortality for patients with mild and severe forms of chronic heart failure were demonstrated in the V-HEFT II, CONSENSUS, and SOLVD trials. Additional benefits were demonstrated with the mineralocorticoid receptor antagonist spironolactone in the RALES trial. These drug classes primarily work by reducing afterload and volume retention. Appreciating why they work for improving cardiac performance and managing symptoms in heart failure patients is straightforward when we consider the major factors that effect cardiac stroke volume - preload, afterload and contractility; however, it is also noteworthy the effects these agents have on sudden death. How beta-blockade benefits the failing heart is less obvious (outside prevention of sudden death). Mechanistic studies in patients with chronic heart failure have consistently shown that when beta blockers are used for more than 1 month, left ventricular function improves. Beta blocker therapy appears to restore the density of beta-adrenergic receptors after they have been downregulated by the chronic overactivity of the sympathetic nervous system. The first major placebo-controlled RCT to demonstrate a mortality benefit used the non-selective beta blocker carvedilol. The trial was small and not originally designed to test mortality and was stopped early without clearly predefined stopping rules. Furthermore, 8% of total patients selected for participation in the trial were excluded prior to randomization after a 2 week, open-label run-in phase with the study drug, which saw 2% of all patients experience worsening heart failure or death representing 24 patients (the difference in total deaths between groups was 9 when the trial was stopped). The Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) was the first large scale trial designed to test the hypothesis that beta-blockade with metoprolol controlled/extended release (CR/XL) added to optimum medical therapy reduces mortality in patients with chronic systolic heart failure.Patients: Patients were recruited from 313 sites in 13 European countries and the United States. Eligible patients were men and women between the age of 40 to 80 years with symptomatic heart failure (NYHA class II-IV) for >/= 3 months before randomization. They had to be on a diuretic and ACE inhibitor for at least 2 weeks. Other drugs, including digoxin, could also be used. Patients also had to have an EF of /=68 beats per minute.Patients were excluded if: they had an MI or unstable angina within 28 days; had an indication or contraindication for treatment with beta-blocker; beta blockade within 6 weeks; heart failure due to systemic disease (i.e., amyloidosis) or alcohol abuse; scheduled or performed cardiac transplant; an ICD; procedures such as CABG or PCI planned or performed in the past 4 months; 2nd or 3rd degree AV block unless a pacemaker was present; unstable or decompensated heart failure defined by pulmonary edema or hypoperfusion or supine systolic BP 25% deviation of the number of observed versus expected consumed placebo tablets during the run-in period.Baseline characteristics: The mean age of patients was 64 years and approximately 78% were male. Slightly more than 30% of patients were above the age of 70. The average EF was 28%. The average SBP was 130 mmHg and heart rate was 82 bpm. Most patients had mild to moderate heart failure, with 41% in NYHA Class II, 56% in Class III, and only 3% in Class IV. Ischemic cardiomyopathy accounted for 65% of cases and nonischemic causes accounted for 35%. Most patients were on an ACE inhibitor or ARB (95%) and diuretic (90%). Digoxin was used in 63%. Trial procedures: Prior to randomization, the study was preceded by a single-blind, 2-week placebo run-in period. Patients meeting eligibility were then randomized to placebo or metoprolol CR/XL. The starting dose of placebo or metoprolol CR/XL was 12.5 mg daily for patients in NYHA class III or IV and 25 mg daily for patients in NYHA class II. The dose was doubled every 2 weeks until the target dose of 200 mg daily was reached. Patients were followed every 3 months.Endpoints: The primary outcome was all-cause mortality. It was estimated that 3,200 patients would need to be followed for 2.4 years to detect a 30% relative reduction in mortality based on annual mortality rate of 9.4% in the placebo group. This would achieve at least 80% power with a 2-sided alpha of 0.04. Patients were recruited faster then planned and so the final sample size of 3,991 patients increased the power of the study.The study was monitored by an independent safety committee and predefined stopping rules for efficacy were based on all-cause mortality, done when 25%, 50%, and 75% of expected deaths had occurred. Results: The trial was stopped early after the 2nd preplanned interim analysis when 50% of expected deaths had occurred. The mean duration of follow-up at the time of stopping was 1 year. The mean daily dose of metoprolol CR/XL was 159 mg once daily, with 87% receiving 100 mg or more and 64% receiving the target dose of 200 mg daily. In the placebo group, the corresponding values were 179 mg daily, 91% and 82%. The study drug was discontinued permanently in 14% of patients in the metoprolol group and 15% in the placebo group. Six months after randomization, heart rate decreased by 14 bpm in the metoprolol group compared to only 3 bpm in the placebo group. Systolic blood pressure decreased less in the metoprolol group (-2.1 vs 3.5 mmHg).Compared to placebo, metoprolol significantly reduced all-cause mortality (7.3% vs 10.8%; RR 0.66; 95% CI 0.53—0.81). Cardiovascular mortality accounted for 91% of all deaths; with sudden death accounting for 58% and death from worsening heart failure accounting for 24% of all deaths. All 3 of these causes of death were significantly reduced by metoprolol. The relative and absolute effects on death were greatest for patients with NYHA class III heart failure.Conclusions: In this trial of stable patients with mild to moderate chronic systolic heart failure, who were optimized on an ACEi or ARB and diuretic, metoprolol CR/XL significantly reduced all-cause mortality. Approximately 30 patients would need to be treated with metoprolol compared to placebo for 1 year to prevent 1 death. This trial represents a significant win for beta blockade in patients with chronic systolic heart failure. While the NNT in this trial is slightly higher than in SOLVD, it is important to appreciate that follow-up time in SOLVD was more than 3x longer. Limitations to external validity in this trial include the run-in period and stringent inclusion and exclusion criteria. Our enthusiasm is also tempered by early stopping, which has been found to be associated with false positive or exaggerated results but this concern is mitigated to some extent in this trial because the rules for early stopping were clearly defined in the protocol.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Selon la revue The Lancet, le monde compte aujourd'hui plus de 800 millions d'adultes atteints par le diabète, soit quatre fois plus qu'en 1990. C'est dans les pays à revenu faible ou intermédiaire que la prévalence a le plus augmenté. Comment expliquer ces chiffres ? Peut-on prévenir cette maladie chronique caractérisée par la présence d'un excès de sucre dans le sang ? Quelles sont les complications du diabète ? Comment les éviter ? Quelles sont les règles d'hygiène à suivre, pour mieux vivre avec son diabète ?  Dr Marine Halbron, diabétologue dans le service de diabétologie de l'Hôpital Pitié-Salpêtrière APHP, à Paris.   Dr David Kodjo Kossi, endocrinologue diabétologue, nutritionniste au CHU Sylvanus Olympio à Lomé, au Togo. Président de l'Association Jeunes Intellect pour la Sécurité Alimentaire au Togo (JISATOGO). Directeur médical du Centre associatif d'éducation thérapeutique du diabète et de l'obésité, DIABEOBE.  Rodrigue Rossignol, Directeur de recherche Inserm et Directeur adjoint de l'unité 1211 Inserm/Université de Bordeaux, Maladies rares : génétique et métabolisme  . En fin d'émission, à la veille de la journée internationale pour l'élimination de la fistule obstétricale célébrée le 23 mai, nous faisons un point sur les actions menées sur le terrain, dans la région de Kolda, au sud du Sénégal. Un reportage de Gwendal Lavina, Correspondant de RFI au Sénégal.  Programmation musicale :► Watendawili - Hadi Kesho ► Valérie Tribord – Mo so

Selon la revue The Lancet, le monde compte aujourd'hui plus de 800 millions d'adultes atteints par le diabète, soit quatre fois plus qu'en 1990. C'est dans les pays à revenu faible ou intermédiaire que la prévalence a le plus augmenté. Comment expliquer ces chiffres ? Peut-on prévenir cette maladie chronique caractérisée par la présence d'un excès de sucre dans le sang ? Quelles sont les complications du diabète ? Comment les éviter ? Quelles sont les règles d'hygiène à suivre, pour mieux vivre avec son diabète ?  Dr Marine Halbron, diabétologue dans le service de diabétologie de l'Hôpital Pitié-Salpêtrière APHP, à Paris.   Dr David Kodjo Kossi, endocrinologue diabétologue, nutritionniste au CHU Sylvanus Olympio à Lomé, au Togo. Président de l'Association Jeunes Intellect pour la Sécurité Alimentaire au Togo (JISATOGO). Directeur médical du Centre associatif d'éducation thérapeutique du diabète et de l'obésité, DIABEOBE.  Rodrigue Rossignol, Directeur de recherche Inserm et Directeur adjoint de l'unité 1211 Inserm/Université de Bordeaux, Maladies rares : génétique et métabolisme  . En fin d'émission, à la veille de la journée internationale pour l'élimination de la fistule obstétricale célébrée le 23 mai, nous faisons un point sur les actions menées sur le terrain, dans la région de Kolda, au sud du Sénégal. Un reportage de Gwendal Lavina, Correspondant de RFI au Sénégal.  Programmation musicale :► Watendawili - Hadi Kesho ► Valérie Tribord – Mo so

India distinguishes itself as one of the worst places in the world to die (Lancet 2015). In rural areas, because of a severe lack of access to appropriate health care, disease often simply ravages the bodies of our precious people completely unchallenged. A host of factors preclude good quality of remaining life, and a good death. Home based palliative care in this scenario is a breath of fresh air, bringing relief, comfort and hope, thus affirming the dignity of human life grounded in Imago Dei Speaker(s): Ashita Singh Session webpage: https://www.medicalmissions.com/events/gmhc-2024/sessions/impact-of-a-replicable-model-of-palliative-care-in-underserved-rural-indian-communities

In this bold and deeply thought-provoking episode, Dr. Nick and Leah Wilson sit down with Dr. Andrew Wakefield to discuss vaccine safety, autism, the power of storytelling through film, and the urgent need for medical transparency. Known for his controversial 1998 Lancet paper that raised questions about the MMR vaccine and autism, Dr. Wakefield reflects on the professional and personal fallout, the science behind his original findings, and the decades-long journey to uncover truth in a system that resists scrutiny. Dr. Wakefield also previews two new films: a COVID-focused narrative shot in Thailand and an upcoming autism project that builds on the stories he's been uncovering for decades. Topics Covered:

As subscribers of Wisdom of Crowds will know, the war in Gaza has preoccupied Shadi Hamid for over a year now, and has taken a central place in his political thinking. Damir Marusic begins this episode by challenging Shadi on this point. Is he giving too much importance to one political and moral cause over all others? And is he giving too much importance to morality as such in geopolitics?The conversation eventually shifts when Damir tells Shadi that he is an “activist” when he writes in favor of a cause, and Shadi disagrees. Writers want to change the world, too, and that does not make them activists. Even Damir (Shadi argues) wants to change the world in some way with his writing. Even Damir has a preferred outcome. But Damir denies this: “My preferred outcome is that people recognize the world is fallen and irredeemable.” Instead, Damir says that it is precisely Trump's “superpower” of being morally indifferent to norms and human rights that has, paradoxically, brought a few positive developments in the Middle East.This is a tense episode, one that digs deep into the psyches of both Shadi and Damir. “Then what?” Shadi retorts. “What's the point of persuading people that the world is irredeemable?” Writing is just playing with words and power, Damir says. It's “a slug trail I leave behind myself.”This episode cuts to the core of Shadi's and Damir's convictions, so we have made it free for all subscribers. You will not want to miss their conversation about Dresden, Hiroshima, Bucha, Trump and the Middle East, and more!Required Reading* “I'm Not As Open-Minded As I Used To Be” (WoC).* “Counting the dead in Gaza: difficult but essential” (The Lancet). * “Gaza will be entirely destroyed, Israeli minister says” (The Guardian). * Pankaj Mishra, “Unholy Alliances” (New Yorker). * Yglesias and Shadi exchange about Trump and the Middle East (X). * Damir's Bucha essay (WoC).* “Trump announces US will stop bombing Houthis” (Politico) This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit wisdomofcrowds.live/subscribe

About this episode: In 2003, George W. Bush's President's Emergency Plan for AIDS Relief (PEPFAR) was the largest commitment to a single disease in U.S. history. Renewed under every subsequent presidency since, PEPFAR has saved more than 25 million lives and prevented some 5 million perinatal infections globally. But now, policy changes that effectively end PEPFAR have the potential to completely reverse course and the world could see HIV/AIDS infections on par with a time even before effective antivirals existed. In this episode: Dr. Chris Beyrer talks about his recent Lancet essay, “On Going Backwards,” why any retreat now will make it harder to regain lost ground, and how this policy change has the potential to impact millions of lives. Guest: Dr. Chris Beyrer is the past president of the International AIDS Society and an expert in global health and human rights. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs at the Johns Hopkins Bloomberg School of Public Health. Show links and related content: On Going Backwards—The Lancet (Perspectives) By executive order: The likely deadly consequences associated with a 90-day pause in PEPFAR funding—Journal of the International AIDS Society Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Chronicling her dual professional life as a highly respected, Lancet-published academic physician while also investigating powerful psychic and paranormal experiences in her work and personal life, Dr. Blackwell presents compelling evidence for telepathy, clairvoyance, near-death experiences (NDEs), life after death, the power of prayer, non-ordinary reality, and more.The book reveals how, after years of attempting to reconcile her extraordinary experiences, Dr. Blackwell transformed from a scientifically trained medic into a mystic, acknowledging there is far more to life - and to us - than science alone can explain. Her irreverent sense of humour (her account of meeting Prince Charles is unmissable) and her ability to integrate both orthodox and complementary medical practices create a thought-provoking, multi-layered, and often amusing read.By sharing her forays into non-ordinary reality, Dr. Blackwell encourages others to share their paranormal experiences without fear of being labelled ‘crazy'.BioFrom humble beginnings as the daughter of a bus driver and market gardener, growing up on a smallholding in rural Wales, Dr. Blackwell, BSc, AKC, FRCP, rose to become a leading authority in genito-urinary medicine. Immersed in orthodox medicine by day, she devoted her after-hours to the in-depth investigation of anomalous phenomena, energy healing, and metaphysics. Her innate psychic abilities offered profound insights into her patients' lives, psyches, and hidden traumas – insights that few modern doctors are privileged to experience.A passionate explorer of the natural world, with a deep-rooted interest in organic gardening, sustainable living and the mysteries of the cosmos, with years of experience in both scientific research and metaphysical studies, Dr. Blackwell shares her unique perspectives and knowledge through engaging blog posts. Her mission is to inspire others to appreciate the wonders of our universe, from the soil beneath our feet to the stars above. You can read more fascinating stories about her own and others' experiences at Dr Blackwell's website, where she encourages those who have had similar experiences to share them with her audience.https://www.amazon.com/dp/B0DV9KZSY5https://www.drblackwell.co.uk/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlifeMy book 'Verified Near Death Experiences' https://www.amazon.com/dp/B0DXKRGDFP

Chronicling her dual professional life as a highly respected, Lancet-published academic physician while also investigating powerful psychic and paranormal experiences in her work and personal life, Dr. Blackwell presents compelling evidence for telepathy, clairvoyance, near-death experiences (NDEs), life after death, the power of prayer, non-ordinary reality, and more.The book reveals how, after years of attempting to reconcile her extraordinary experiences, Dr. Blackwell transformed from a scientifically trained medic into a mystic, acknowledging there is far more to life - and to us - than science alone can explain. Her irreverent sense of humour (her account of meeting Prince Charles is unmissable) and her ability to integrate both orthodox and complementary medical practices create a thought-provoking, multi-layered, and often amusing read.By sharing her forays into non-ordinary reality, Dr. Blackwell encourages others to share their paranormal experiences without fear of being labelled ‘crazy'.BioFrom humble beginnings as the daughter of a bus driver and market gardener, growing up on a smallholding in rural Wales, Dr. Blackwell, BSc, AKC, FRCP, rose to become a leading authority in genito-urinary medicine. Immersed in orthodox medicine by day, she devoted her after-hours to the in-depth investigation of anomalous phenomena, energy healing, and metaphysics. Her innate psychic abilities offered profound insights into her patients' lives, psyches, and hidden traumas – insights that few modern doctors are privileged to experience.A passionate explorer of the natural world, with a deep-rooted interest in organic gardening, sustainable living and the mysteries of the cosmos, with years of experience in both scientific research and metaphysical studies, Dr. Blackwell shares her unique perspectives and knowledge through engaging blog posts. Her mission is to inspire others to appreciate the wonders of our universe, from the soil beneath our feet to the stars above. You can read more fascinating stories about her own and others' experiences at Dr Blackwell's website, where she encourages those who have had similar experiences to share them with her audience.https://www.amazon.com/dp/B0DV9KZSY5https://www.drblackwell.co.uk/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlifeMy book 'Verified Near Death Experiences' https://www.amazon.com/dp/B0DXKRGDFP

Join Dr. Damon Arnold, retired U.S. Army combat medic and host of America's Heroes Group, as he speaks with Susan Jaffe, a contributing writer for KFF Health News and the DC Correspondent for The Lancet. In this compelling discussion, they delve into Jaffe's recent article, "When Hospitals Ditch Medicare Advantage Plans, Thousands of Members Get to Leave Too," published on April 28, 2025. Learn about the complex dynamics behind hospitals opting out of Medicare Advantage plans, the impact on beneficiaries, and the special enrollment periods that can provide relief.Topics:Overview of Medicare and Medicare Advantage PlansWhy Hospitals Leave Medicare Advantage NetworksThe Impact on Patients and ProvidersSpecial Enrollment Periods and Patient RightsDifferences Between Urban and Rural Access to CareHow to Navigate Medicare Advantage Plan ChangesLegislative Responses and Consumer AdvocacyResources for Affected Patients and Families

The DOJ is investigating top medical journals for biased editorial practices, alleging they suppressed studies on COVID-19 vaccine risks and alternative therapeutics for partisan reasons. NBC reports the science publications (including CHEST, New England Journal of Medicine, and Obstetrics and Gynecology) were sent letters “questioning their editorial practices.” In response, medical journal The Lancet called the letters “harassment” and claimed science in the USA was being “violently dismembered” by all of these annoying questions being asked by the peasants. “This corrupt web of suppression, fraud, and retractions demands a legal reckoning,” writes epidemiologist Nicolas Hulscher. Dr. Ram Yogendra, MD, MHP, is a board-certified anesthesiologist with a public health background. He advocates for vaccine injury research, highlighting issues like the persistence of S1 spike protein in monocytes post-COVID-19 vaccination. More at https://x.com/dryostradamus and https://covidlonghaulers.com Elijah Schaffer is a journalist for The Gateway Pundit and the host of Slightly Offensive on Censored.TV. He's also a news presenter on Vigilant News Network. Schaffer filmed the Kyle Rittenhouse shootings, was inside the Capitol on January 6, 2021, and went undercover in groups like Antifa and BLM during the 2020 riots. More at https://x.com/ElijahSchaffer 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠https://drdrew.com/sponsors⁠⁠  ⁠⁠⁠ • FRESH PRESSED OLIVE OIL – Olive oil packs the most flavor and healthiest nutrients when it's fresh. Don't settle for stale supermarket olive oils – get it direct from small, award-winning farms! Get your free $39 bottle for just $1 shipping & taste the difference at ⁠https://GetFreshDrDrew.com/ • ACTIVE SKIN REPAIR - Repair skin faster with more of the molecule your body creates naturally! Hypochlorous (HOCl) is produced by white blood cells to support healing – and no sting. Get 20% off at ⁠⁠https://drdrew.com/skinrepair⁠⁠ • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠https://drdrew.com/fatty15⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠https://drdrew.com/paleovalley⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠https://twc.health/drew⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠https://kalebnation.com⁠⁠) and Susan Pinsky (⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠e⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

Chaque jour, en moins de 10 minutes, un résumé de l'actualité du jour. Rapide, facile, accessible.

In this first webinar of RheumNow's Lupus Unlocked campaign, Journal Club discussed two articles: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Furie R, et al. NEJM. 2025 Feb 7. doi: 10.1056 Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1) Rovin BH. Lancet. 2021 May 29;397(10289) Speakers: Brad Rovin, MD Richard Furie, MD Jack Cush, MD

Join Sandra Champlain on the We Don't Die podcast as she interviews Dr. Anona Blackwell, author of "From Medic to Mystic." Dr. Blackwell shares her remarkable journey from a highly respected, Lancet-published academic physician to an investigator of powerful psychic and paranormal experiences. Discover compelling evidence for telepathy, clairvoyance, near-death experiences (NDEs), life after death, and the power of prayer. Dr. Blackwell's innate psychic abilities offered profound insights into her patients' lives, psyches, and hidden traumas. This is a thought-provoking and often amusing conversation about integrating orthodox and complementary medical practices and exploring the mysteries beyond the physical world. Find Dr. Blackwell's book at https://amzn.to/42fysNB and website https://www.drblackwell.co.uk/ Thank you for listening! Be sure to also listen to Sandra's show on iHeart Radio "Shades of the Afterlife" https://bit.ly/ShadesoftheAfterlife  *Join our free Sunday Gathering Inspirational Service, with medium demonstration included, PLUS medium & afterlife classes and events at https://www.wedontdie.com **Join our Patreon Community for as little as $1 per episode and receive ad-free, early bird episodes, and a full clickable & searchable list off all Sandra's over 700 afterlife episodes https://www.patreon.com/wedontdieradio **Join the supportive and loving, We Don't Die Listeners Facebook group at https://www.facebook.com/groups/wedontdielisteners/

Listen as we discuss the highly-awaited ESOPEC trial, which examines treatment regimens for esophageal and EGJ adenocarcinoma. Wildly impress your thoracic attendings or peers with your nuanced knowledge! FLOT who? You'll know. Pull out the paper and listen along! Learning Objectives: -Discuss the patient population in the ESOPEC trial -Discuss the main differences between the ESOPEC trial and the CROSS trial -Describe the main drawbacks between FLOT and the CROSS regimen. Hosts: Chloe Hanson MD, Brian Louie MD, and Peter White MD   Referenced Material https://www.nejm.org/doi/full/10.1056/NEJMoa2409408 Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, Utzolino S, Izbicki JR, Gockel I, Gerdes B, Ghadimi M, Reichert B, Lock JF, Bruns C, Reitsamer E, Schmeding M, Benedix F, Keck T, Folprecht G, Thuss-Patience P, Neumann UP, Pascher A, Imhof D, Daum S, Strieder T, Krautz C, Zimmermann S, Werner J, Mahlberg R, Illerhaus G, Grimminger P, Lordick F. Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. N Engl J Med. 2025 Jan 23;392(4):323-335. doi: 10.1056/NEJMoa2409408. PMID: 39842010. https://www.nejm.org/doi/full/10.1056/NEJMoa1112088 van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088. PMID: 22646630. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32557-1/abstract Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. PMID: 30982686. ***Fellowship Application Link: https://forms.gle/PQgAvGjHrYUqAqTJ9 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen